PBIM (135) № 2 2022
Subject of the article
MECHANISMS OF ACTION OF NON-STEROID ANTI-INFLAMMATORY DRUGS IN THE DEVELOPMENT OF GASTROPATHY (24-27)
Authors
Daminova Lola Turgunpulatovna, Abdashimov Zafar Bakhtiyarovich
Institution
Tashkent State Dental Institute, Republic of Uzbekistan, Tashkent
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of commonly used medicines. An important issue with NSAIDs is gastrointestinal (GI) side reactions at various levels, from dyspepsia to life-threatening complications such as bleeding or wound perforation. The above words confirm that this article is relevant today.
Key words
NSAIDs, gastrointestinal tract, dyspepsia, bleeding, mechanism.
Literature
1. Klyaritskaya I.L., Rabotyagova Yu.S. CYP2C19 gen polimorfizmi va uning ta'rifining klinik ahamiyati. Qrim terapevtik jurnali 2013; 1: 19-25. 2. "Klinik amaliyotda steroid bo'lmagan yallig'lanishga qarshi dorilarni (NSAID) oqilona qo'llash" klinik ko'rsatmalari. Zamonaviy revmatologiya. 2015; 1: 4-23. 3. Obzherina A.Yu., Sychev DA, Muravyova Yu.V., Ignatiev IV, Dmitriev VA, Kukes VT CYP2C9 polimorfizmi: steroid bo'lmagan yallig'lanishga qarshi preparatlarni qo'llash bilan oshqozon-ichak traktining asoratlari rivojlanishi uchun yangi xavf omili. Klinik farmakologiya va farmakoiqtisodiyot. 2009; 2 (5): 20-5. 4. Blanco G., Martínez C., Ladero J.M. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. // Pharmacogenet Genomics. – 2008. - vol.18(1). – P. 37–43. 5. Carbonell N., Verstuyft C., Massard J. CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin // Clin. Pharmacol. Ther. – 2010. - vol.87(6). – P. 693–698. 6. Denisenko NP, Sychev DA, Sizova ZM, et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmgenomics Pers Med. 2017;10:253–259. DOI: 10.2147/PGPM.S141935 7. Estany-Gestal A., Salgado-Barreira A., Sánchez-Diz P., Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review. // Pharmacogenet. Genomics. – 2011. -vol. 21(7). – P. 357–364. 8. Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16(4):223–234. DOI: 10.2165/11634960-000000000-00000 9. Hunfeld N.G., Mathot R.A., Touw D.J. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians // Br. J. Clin. Pharmacol. – 2008. – vol. 65(5). – P. 752–760. 10. Hunt R.H., Lanas A., Stichtenoth D.O., Scarpignato C. Myths and facts in the use of anti-inflammatory drugs //Ann. Med. – 2009. - Vol. 41(6). – P. 423–437. 11. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers Baldwin R.M., Ohlsson S., Pedersen R.S. et al. //Br. J. Clin. Pharmacol. – 2008. – vol. 65(5). – P. 767–774. 12. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects // Pharmacol. Ther. – 2007. – vol.116(3). – P. 496–526. 13. Kaspera R., Totah R.A. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology // Expert Opin. Drug Metab. Toxicol. – 2009. – vol.5(7). – P. 757–771. 14. Li-Wan-Po A., Girard T., Farndon P. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. // Br. J. Clin. Pharmacol. – 2010. – vol. 69(3): 222–230. 15. Ma J., Yang X.Y., Qiao L. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy // J. Dig. Dis. – 2008. – vol. 9(2): 79–83. 16. Martínez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2): 205–208. DOI: 10.1038/sj.bjp.0705623 17. Musumba C.O., Jorgensen A., Sutton L. et al. (2013) CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease // Clin. Pharmacol. Ther. 2013. - 93(2): 195–203. 18. Pedersen R.S., Brasch-Andersen C., Sim S.C. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations // Eur. J. Clin. Pharmacol. – 2010. – vol. 66(12): 1199–1205. 19. Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465–471. 20. Preissner SC, Hoffmann MF, Preissner R Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLoS One 2013;8(12): e82562. 21. Scott S.A., Martis S., Peter I. et al. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness // Pharmacogenomics J. – 2012. – vol. 12(4): 297–305. 22. Vogl S, Lutz RW, Schönfelder G, Lutz WK. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. PLoS One. 2015 Mar 16;10(3):e0120403. DOI: 10.1371/journal.pone.0120403